Stay updated with breaking news from 46433010. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note published on Thursday morning. The firm issued a hold rating on the stock. Other equities analysts have also recently issued reports about the company. VNET Group reiterated a maintains rating on shares of Ionis Pharmaceuticals in a report on […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Investment analysts at William Blair cut their Q3 2023 earnings estimates for Ionis Pharmaceuticals in a report issued on Wednesday, August 9th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.94) by $1.54, reports. The business had revenue of $188.00 million during the quarter, compared to analysts’ expectations of $136.84 million. Ionis Pharmaceuticals had a negative net margin […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) Director Allene M. Diaz sold 657 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $41.05, for a total transaction of $26,969.85. Following the sale, the director now directly owns 12,676 shares of the […]